HRP20040660B1 - 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI - Google Patents
2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONIInfo
- Publication number
- HRP20040660B1 HRP20040660B1 HRP20040660AA HRP20040660A HRP20040660B1 HR P20040660 B1 HRP20040660 B1 HR P20040660B1 HR P20040660A A HRP20040660A A HR P20040660AA HR P20040660 A HRP20040660 A HR P20040660A HR P20040660 B1 HRP20040660 B1 HR P20040660B1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrido
- ylamino
- pyrimidin
- pyridin
- ones
- Prior art date
Links
- 150000003930 2-aminopyridines Chemical class 0.000 abstract 1
- 108091007914 CDKs Proteins 0.000 abstract 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 abstract 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
Abstract
<IMAGE NAME="20040660_01" TYPE="jpg" CENTER=TRUE/><BR/>Ovaj izum omogućuje supstituirane 2-aminopiridine koji su korisni u liječenju poremećaja proliferacije stanica. Novi spojevi iz ovog izuma su snažni inhibitori ciklin-ovisnih kinaza 4 (cdk4).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35087702P | 2002-01-22 | 2002-01-22 | |
PCT/IB2003/000059 WO2003062236A1 (en) | 2002-01-22 | 2003-01-10 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20040660A2 HRP20040660A2 (en) | 2004-12-31 |
HRP20040660B1 true HRP20040660B1 (hr) | 2012-10-31 |
Family
ID=27613435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20040660AA HRP20040660B1 (hr) | 2002-01-22 | 2004-07-19 | 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI |
Country Status (53)
Families Citing this family (298)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
CA2424057A1 (en) * | 2000-08-04 | 2003-04-03 | Warner-Lambert Company | Process for preparing 2-(4-pyridyl) amino-6-dialkyloxyphenyl-pyrido [2,3-d]pyrimidin-7-ones |
US6960662B2 (en) * | 2000-08-04 | 2005-11-01 | Warner-Lambert Company | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones |
CA2434834C (en) * | 2001-02-12 | 2010-09-14 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
MXPA03007623A (es) | 2001-02-26 | 2003-12-04 | Tanabe Seiyaku Co | Derivado de piridopirimidina o naftiridina. |
US20030100572A1 (en) * | 2001-06-21 | 2003-05-29 | Ariad Pharmaceuticals,Inc. | Novel pyridopyrimidones and uses thereof |
US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
RU2324695C2 (ru) * | 2002-08-06 | 2008-05-20 | Ф.Хоффманн-Ля Рош Аг | 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38 |
US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
AU2003288994A1 (en) * | 2002-12-10 | 2004-06-30 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compounds and medicinal use thereof |
EP1615928A1 (en) | 2003-04-10 | 2006-01-18 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
PL1648889T3 (pl) * | 2003-07-11 | 2009-03-31 | Warner Lambert Co | Sól izetionian selektywnego inhibitora CDK4 |
NZ544756A (en) | 2003-07-22 | 2009-09-25 | Astex Therapeutics Ltd | 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
ATE556056T1 (de) | 2003-07-29 | 2012-05-15 | Xenon Pharmaceuticals Inc | Pyridylderivate und deren verwendung als therapeutische mittel |
EP1685131B1 (en) * | 2003-11-13 | 2007-03-07 | F. Hoffmann-La Roche AG | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
EP1699477A2 (en) * | 2003-12-11 | 2006-09-13 | Theravance, Inc. | Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases |
DK1713806T3 (da) * | 2004-02-14 | 2013-08-05 | Irm Llc | Forbindelser og sammensætninger som proteinkinaseinhibitorer |
WO2005082903A1 (en) * | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
WO2005094830A1 (en) * | 2004-03-30 | 2005-10-13 | Pfizer Products Inc. | Combinations of signal transduction inhibitors |
US7378423B2 (en) | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
PT2298768E (pt) * | 2004-06-11 | 2012-12-05 | Japan Tobacco Inc | Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro |
JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
CN101146533A (zh) * | 2005-01-21 | 2008-03-19 | 阿斯泰克斯治疗有限公司 | 吡唑激酶抑制剂和其它抗肿瘤剂的组合 |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
BRPI0606480A (pt) * | 2005-01-21 | 2008-03-11 | Astex Therapeutics Ltd | compostos farmacêuticos |
MX2007008781A (es) * | 2005-01-21 | 2007-09-11 | Astex Therapeutics Ltd | Compuestos farmaceuticos. |
EP1852432A4 (en) * | 2005-02-25 | 2010-04-14 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUND AND THEIR MEDICAL USE |
PE20100741A1 (es) * | 2005-03-25 | 2010-11-25 | Glaxo Group Ltd | COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38 |
PE20061351A1 (es) * | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
BRPI0608604B8 (pt) | 2005-05-10 | 2021-05-25 | Incyte Corp | moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica |
KR100734837B1 (ko) * | 2005-09-16 | 2007-07-03 | 한국전자통신연구원 | 다중 생체 인식 시스템 및 그 방법 |
EP1931667A1 (en) * | 2005-09-28 | 2008-06-18 | Ranbaxy Laboratories Limited | Pyrido-pyridimidine derivatives useful as antiinflammatory agents |
EP1931670B1 (en) * | 2005-10-07 | 2012-09-12 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of pi3k |
KR101492795B1 (ko) * | 2005-10-07 | 2015-02-13 | 엑셀리시스, 인코포레이티드 | PI3Kα의 피리도피리미디논 억제제 |
US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
EP2032134B1 (en) | 2006-05-09 | 2015-06-24 | Genzyme Corporation | Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis |
KR20090052385A (ko) * | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성 |
MY146420A (en) | 2006-09-15 | 2012-08-15 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors |
WO2008150260A1 (en) * | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
EP1914234A1 (en) | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
BRPI0715566A2 (pt) * | 2006-10-16 | 2013-07-02 | Gpc Biotech Inc | composto, prà-droga, composiÇço farmacÊutica, uso de um composto, mÉtodo para inibir a proliferaÇço de cÉlulas e mÉtodo para sintetizar um composto |
CN101535308A (zh) * | 2006-11-09 | 2009-09-16 | 霍夫曼-拉罗奇有限公司 | 作为激酶抑制剂的取代的6-苯基-吡啶并[2,3-d]嘧啶-7-酮衍生物及其使用方法 |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
SG10201707161PA (en) | 2007-10-05 | 2017-10-30 | Genzyme Corp | Method of treating polycystic kidney diseases with ceramide derivatives |
AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
WO2009126584A1 (en) | 2008-04-07 | 2009-10-15 | Amgen Inc. | Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors |
EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
PT2824100T (pt) | 2008-07-08 | 2018-05-10 | Incyte Holdings Corp | 1,2,5-oxadiazoles como inibidores da indoleamina 2,3-dioxigenase |
JP2011529500A (ja) | 2008-07-28 | 2011-12-08 | ジェンザイム コーポレーション | 虚脱性糸球体症および他の糸球体疾患の処置のためのグルコシルセラミドシンターゼ阻害 |
MX2011001879A (es) * | 2008-08-22 | 2011-03-29 | Novartis Ag | Compuestos de pirrolo-pirimidina como inhibidores de cdk. |
US20110224221A1 (en) * | 2008-10-01 | 2011-09-15 | Sharpless Norman E | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
AU2009298367A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
US8309593B2 (en) | 2008-10-03 | 2012-11-13 | Genzyme Corporation | 2-acylaminopropoanol-type glucosylceramide synthase inhibitors |
PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
CN110269838A (zh) | 2009-04-03 | 2019-09-24 | 豪夫迈罗氏公司 | 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途 |
US20120100100A1 (en) | 2009-05-13 | 2012-04-26 | Sharpless Norman E | Cyclin dependent kinase inhibitors and methods of use |
JPWO2011025006A1 (ja) * | 2009-08-31 | 2013-01-31 | 日本ケミファ株式会社 | Gpr119作動薬 |
WO2011044535A2 (en) * | 2009-10-09 | 2011-04-14 | Afraxis, Inc. | 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
CA2780190C (en) | 2009-11-06 | 2020-05-05 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2011075616A1 (en) * | 2009-12-18 | 2011-06-23 | Temple University - Of The Commonwealth System Of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof |
AU2010338038B2 (en) | 2009-12-31 | 2015-07-09 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Tricyclic compounds for use as kinase inhibitors |
JP5918214B2 (ja) | 2010-04-13 | 2016-05-18 | ノバルティス アーゲー | がんを治療するためのサイクリン依存性キナーゼ4またはサイクリン依存性キナーゼ(cdk4/6)阻害剤およびmtor阻害剤を含む組合せ |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
US8680099B2 (en) * | 2010-06-10 | 2014-03-25 | Afraxis Holdings, Inc. | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders |
EP2580320B1 (en) | 2010-06-14 | 2018-08-01 | The Scripps Research Institute | Reprogramming of cells to a new fate |
DK2600719T3 (da) | 2010-08-05 | 2014-12-15 | Univ Temple | 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf |
EP3118203B1 (en) | 2010-10-25 | 2018-10-24 | G1 Therapeutics, Inc. | Cdk inhibitors |
US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
US9808461B2 (en) | 2010-11-17 | 2017-11-07 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
LT2672967T (lt) | 2011-02-07 | 2018-12-10 | Plexxikon Inc. | Junginiai ir būdai skirti kinazės moduliavimui, ir jų indikacijos |
KR20160035613A (ko) * | 2011-03-23 | 2016-03-31 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
RU2013157898A (ru) | 2011-05-27 | 2015-07-10 | Темпл Юниверсити-Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | ЗАМЕЩЕННЫЕ 2-БЕНЗИЛИДЕН-2H-БЕНЗО[b][1,4]ТИАЗИН-3(4H)-ОНЫ, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПЕВТИЧЕСКИХ ЦЕЛЯХ |
EA028232B1 (ru) * | 2012-03-14 | 2017-10-31 | Люпин Лимитед | Гетероциклильные соединения как ингибиторы mek |
EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP3822273B1 (en) | 2012-06-13 | 2024-04-10 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
PL2872491T3 (pl) | 2012-07-11 | 2021-12-13 | Blueprint Medicines Corporation | Inhibitory receptora czynnika wzrostu fibroblastów |
AU2013296237B2 (en) | 2012-08-03 | 2019-05-16 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
MX361499B (es) | 2012-08-17 | 2018-12-06 | Concert Pharmaceuticals Inc | Baricitinib deuterado. |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014109858A1 (en) | 2013-01-14 | 2014-07-17 | Amgen Inc. | Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture |
MX363715B (es) | 2013-02-21 | 2019-03-29 | Pfizer | Formas solidas de un inhbidor de cdk4/6 selectivo. |
EA032094B1 (ru) * | 2013-03-15 | 2019-04-30 | Консерт Фармасьютикалс, Инк. | Дейтерированный палбоциклиб |
CA2906157C (en) | 2013-03-15 | 2022-05-17 | G1 Therapeutics, Inc. | Highly active anti-neoplastic and anti-proliferative agents |
LT2968290T (lt) | 2013-03-15 | 2019-12-10 | G1 Therapeutics Inc | Laikina normalių ląstelių apsauga chemoterapijos metu |
TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
CN104470921B (zh) * | 2013-05-17 | 2017-05-03 | 上海恒瑞医药有限公司 | 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用 |
WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
DK3395814T3 (da) | 2013-10-25 | 2022-07-04 | Blueprint Medicines Corp | Hæmmere af fibroblastvækstfaktorreceptoren |
EP3082423A4 (en) * | 2013-12-20 | 2017-09-20 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of cdk and erk inhibitors |
CN105916848B (zh) | 2013-12-31 | 2018-01-09 | 山东轩竹医药科技有限公司 | 激酶抑制剂及其用途 |
US9949976B2 (en) | 2013-12-31 | 2018-04-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
US20150297607A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy |
US10555931B2 (en) | 2014-05-28 | 2020-02-11 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
US9878994B2 (en) * | 2014-07-24 | 2018-01-30 | Beta Pharma Inc. | 2-H-indazole derivatives as cyclin-dependent kinase (CDK) inhibitors and therapeutic uses thereof |
EP3172214B1 (en) * | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
EP3174878A4 (en) * | 2014-07-31 | 2017-12-27 | Sun Pharmaceutical Industries Limited | A process for the preparation of palbociclib |
US20170224819A1 (en) * | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
US20170240543A1 (en) * | 2014-08-14 | 2017-08-24 | Sun Pharmaceutical Industries Limited | Crystalline forms of palbociclib |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
CN105111201B (zh) * | 2014-10-16 | 2017-01-11 | 上海页岩科技有限公司 | 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN105622638B (zh) * | 2014-10-29 | 2018-10-02 | 广州必贝特医药技术有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用 |
WO2016066420A1 (en) * | 2014-10-29 | 2016-05-06 | Sandoz Ag | Crystalline forms of palbociclib monohydrochloride |
CN105616418A (zh) * | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
DK3218005T3 (da) | 2014-11-12 | 2023-03-27 | Seagen Inc | Glycan-interagerende forbindelser og anvendelsesfremgangsmåder |
CN104496983B (zh) * | 2014-11-26 | 2016-06-08 | 苏州明锐医药科技有限公司 | 一种帕博西尼的制备方法 |
CN104447743B (zh) * | 2014-11-26 | 2016-03-02 | 苏州明锐医药科技有限公司 | 帕博西尼的制备方法 |
WO2016090257A1 (en) * | 2014-12-05 | 2016-06-09 | Crystal Pharmatech Inc. | Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib) |
WO2016092442A1 (en) * | 2014-12-08 | 2016-06-16 | Sun Pharmaceutical Industries Limited | Processes for the preparation of crystalline forms of palbociclib acetate |
CN105732615B (zh) * | 2014-12-31 | 2018-05-01 | 山东轩竹医药科技有限公司 | Cdk激酶抑制剂 |
WO2016107605A1 (zh) | 2014-12-31 | 2016-07-07 | 昆明积大制药股份有限公司 | 药物组合物及其制备方法 |
CN104610254B (zh) * | 2015-01-26 | 2017-02-01 | 新发药业有限公司 | 一种帕博赛布的低成本制备方法 |
CZ201589A3 (cs) | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
TWI690533B (zh) | 2015-02-12 | 2020-04-11 | 南北兄弟藥業投資有限公司 | Cdk類小分子抑制劑的化合物及其用途 |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
EP3078663A1 (en) | 2015-04-09 | 2016-10-12 | Sandoz Ag | Modified particles of palbociclib |
CN106795159B (zh) * | 2015-04-22 | 2018-12-28 | 江苏恒瑞医药股份有限公司 | 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法 |
TWI696617B (zh) | 2015-04-28 | 2020-06-21 | 大陸商上海復尚慧創醫藥研究有限公司 | 特定蛋白質激酶抑制劑 |
WO2016194831A1 (ja) * | 2015-05-29 | 2016-12-08 | 帝人ファーマ株式会社 | ピリド[3,4-d]ピリミジン誘導体及びその薬学的に許容される塩 |
KR102369405B1 (ko) * | 2015-06-04 | 2022-03-02 | 화이자 인코포레이티드 | 팔보시클립의 고체 투여 형태 |
CN104892604B (zh) * | 2015-06-19 | 2016-08-24 | 北京康立生医药技术开发有限公司 | 一种cdk4抑制剂的合成方法 |
CN106699785A (zh) * | 2015-07-13 | 2017-05-24 | 南开大学 | 作为CDK4/6抑制剂的2-(N-氧化吡啶-2基氨基)-吡啶并[2,3-d]嘧啶-7-酮类化合物 |
EP3543235A1 (en) | 2015-08-05 | 2019-09-25 | ratiopharm GmbH | Crystalline form and acetic acid adduct of palbociclib |
CN105085517B (zh) * | 2015-08-06 | 2016-11-23 | 天津华洛康生物科技有限公司 | 一种结晶型帕博西尼游离碱水合物及其制备方法 |
CN105130986B (zh) * | 2015-09-30 | 2017-07-18 | 广州科擎新药开发有限公司 | 嘧啶或吡啶并吡啶酮类化合物及其应用 |
HU230962B1 (hu) | 2015-10-28 | 2019-06-28 | Egis Gyógyszergyár Zrt. | Palbociclib sók |
CN106632311B (zh) * | 2015-11-02 | 2021-05-18 | 上海科胜药物研发有限公司 | 一种帕博西尼晶型a和晶型b的制备方法 |
KR20180088381A (ko) | 2015-11-12 | 2018-08-03 | 시아맙 쎄라퓨틱스, 인코포레이티드 | 글리칸-상호작용 화합물 및 사용방법 |
CN105418603A (zh) * | 2015-11-17 | 2016-03-23 | 重庆莱美药业股份有限公司 | 一种高纯度帕布昔利布及其反应中间体的制备方法 |
CN106810536A (zh) * | 2015-11-30 | 2017-06-09 | 甘李药业股份有限公司 | 一种蛋白激酶抑制剂及其制备方法和医药用途 |
CN108699055B (zh) * | 2015-12-13 | 2020-10-23 | 杭州英创医药科技有限公司 | 用作抗癌药物的杂环化合物 |
CN105418609B (zh) * | 2015-12-31 | 2017-06-23 | 山东大学 | 4‑(1,2,3‑三氮唑取代苯胺基)‑吡啶骈嘧啶酮衍生物及其制备方法与应用 |
CN106928219B (zh) | 2015-12-31 | 2021-08-20 | 上海医药集团股份有限公司 | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 |
CN106967061A (zh) * | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
WO2017130219A1 (en) | 2016-01-25 | 2017-08-03 | Mylan Laboratories Limited | Amorphous solid dispersion of palbociclib |
WO2017145054A1 (en) | 2016-02-24 | 2017-08-31 | Lupin Limited | Modified particles of crystalline palbociclib free base and process for the preparation thereof |
US11077110B2 (en) | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
CN107266421B (zh) * | 2016-04-08 | 2020-12-04 | 正大天晴药业集团股份有限公司 | 取代的苯并咪唑类衍生物 |
CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
CA3018434A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
CN106336411B (zh) * | 2016-04-27 | 2018-03-06 | 上海医药集团股份有限公司 | Cdk4/6抑制剂帕博西尼高纯度原料药的制备工艺及用途 |
CN105949189B (zh) * | 2016-06-05 | 2017-09-22 | 童明琼 | 一种用于治疗乳腺癌的帕博西尼的制备方法 |
RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
WO2018007927A1 (en) | 2016-07-04 | 2018-01-11 | Dr. Reddy's Laboratories Limited | Process for preparation of palbociclib |
MX2019000246A (es) | 2016-07-07 | 2019-05-27 | Plantex Ltd | Formas en estado solido del dimesilato de palbociclib. |
UA124804C2 (uk) * | 2016-08-15 | 2021-11-24 | Пфайзер Інк. | Піридопіримідинонові інгібітори cdk2/4/6 |
US20190175598A1 (en) | 2016-08-23 | 2019-06-13 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of hepatocellular carcinoma |
US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
WO2018065999A1 (en) | 2016-10-07 | 2018-04-12 | Mylan Laboratories Limited | Novel polymorph of an intermediate for palbociclib synthesis |
RU2019111887A (ru) | 2016-10-20 | 2020-11-20 | Пфайзер Инк. | Антипролиферативные средства для лечения лаг |
WO2018073574A1 (en) | 2016-10-20 | 2018-04-26 | Cipla Limited | Polymorphic forms of palbociclib |
CN106565707B (zh) * | 2016-11-03 | 2019-01-04 | 杭州科巢生物科技有限公司 | 帕博西尼新合成方法 |
EP3538148A1 (en) | 2016-11-08 | 2019-09-18 | Dana-Farber Cancer Institute | Compositions and methods of modulating anti-tumor immunity |
WO2018091999A1 (en) | 2016-11-16 | 2018-05-24 | Pfizer Inc. | Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE |
CA3043561A1 (en) | 2016-11-28 | 2018-05-31 | Teijin Pharma Limited | Pyrido[3,4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
KR102352637B1 (ko) | 2016-11-28 | 2022-01-17 | 데이진 화-마 가부시키가이샤 | 피리도[3,4-d]피리미딘 유도체 또는 그 용매화물의 결정 |
US10676474B2 (en) | 2016-12-16 | 2020-06-09 | Cstone Pharmaceuticals | 1,6-naphthyridine derivatives as CDK4/6 inhibitor |
AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
CN108191857B (zh) * | 2017-01-24 | 2020-10-23 | 晟科药业(江苏)有限公司 | 6-取代的吡啶并[2,3-d]嘧啶类化合物作为蛋白激酶抑制剂 |
US10729692B2 (en) * | 2017-02-26 | 2020-08-04 | Institute For Cancer Research | Dual inhibition of CDK and HSP90 destabilize HIF1alpha and synergistically induces cancer cell death |
JP7226804B2 (ja) * | 2017-03-03 | 2023-02-21 | オークランド ユニサービシズ リミテッド | Fgfrキナーゼ阻害剤及び医薬用途 |
AU2018226824A1 (en) | 2017-03-03 | 2019-09-19 | Seagen Inc. | Glycan-interacting compounds and methods of use |
MX2019010981A (es) | 2017-03-16 | 2020-09-07 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de cancer de mama. |
CN108658855A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种含氮双环化合物及其制备方法和用途 |
CN108658854A (zh) * | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种生物碱化合物及其制备方法和作为海洋防污剂的应用 |
WO2018183921A1 (en) | 2017-04-01 | 2018-10-04 | The Broad Institute, Inc. | Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
BR112019026483A2 (pt) | 2017-06-16 | 2020-07-14 | Beta Pharma, Inc. | formulação farmacêutica de n-(2-(2-(dimetilamina)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amina)fenil)acrilamida e seus sais |
RU2019142591A (ru) | 2017-06-29 | 2021-07-29 | Г1 Терапьютикс, Инк. | Морфологические формы g1t38 и способы их получения |
EA036060B1 (ru) * | 2017-07-17 | 2020-09-21 | Пфайзер Инк. | Пиридопиримидиноновые ингибиторы cdk2/4/6 |
EA202090402A1 (ru) | 2017-07-28 | 2020-05-19 | Синтон Б.В. | Фармацевтическая композиция, содержащая пальбоциклиб |
CN109384767B (zh) * | 2017-08-08 | 2020-05-05 | 江苏恒瑞医药股份有限公司 | 一种吡啶并嘧啶类衍生物的制备方法及其中间体 |
CN111433375A (zh) | 2017-08-31 | 2020-07-17 | 诺华股份有限公司 | 选择针对癌症患者的治疗的方法 |
CN107488175A (zh) * | 2017-09-04 | 2017-12-19 | 上海微巨实业有限公司 | 一种帕博西林关键中间体的制备方法 |
CA3085366A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
KR20200115583A (ko) | 2018-01-29 | 2020-10-07 | 베타 파마, 인크. | Cdk4 및 cdk6 억제제로서의 2h-인다졸 유도체 및 그의 치료 용도 |
CN108218861B (zh) * | 2018-02-05 | 2019-07-23 | 黑龙江中医药大学 | 一种预防和治疗糖尿病的药物及其制备方法 |
EP3749654A4 (en) | 2018-02-06 | 2021-11-03 | The Board of Trustees of the University of Illinois | BENZOTHIOPHENE ANALOGUES SUBSTITUTED AS SELECTIVE ESTROGEN RECEPTOR DEGRADATION AGENTS |
CN117903140A (zh) | 2018-02-27 | 2024-04-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
EP3758753A1 (en) | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2019220253A1 (en) | 2018-05-14 | 2019-11-21 | Pfizer Inc. | Oral solution formulation |
MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
SI3802529T1 (sl) | 2018-05-24 | 2024-03-29 | Synthon B.V. | Postopek za izdelavo palbocikliba |
JP7490631B2 (ja) | 2018-07-05 | 2024-05-27 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピラジン誘導体 |
MX2021000847A (es) | 2018-07-23 | 2021-03-26 | Hoffmann La Roche | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. |
SG11202101807SA (en) | 2018-08-24 | 2021-03-30 | G1 Therapeutics Inc | Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one |
JP6952747B2 (ja) | 2018-09-18 | 2021-10-20 | ファイザー・インク | がん処置のためのTGFβ阻害剤およびCDK阻害剤の組合せ |
WO2020076432A1 (en) | 2018-10-08 | 2020-04-16 | Genentech, Inc. | Methods of treating cancer with pi3k alpha inhibitors and metformin |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
TW202035406A (zh) * | 2018-12-07 | 2020-10-01 | 大陸商杭州英創醫藥科技有限公司 | 作為cdk-hdac雙通路抑制劑的雜環化合物 |
AU2019407426A1 (en) | 2018-12-21 | 2021-07-22 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
US20230048132A1 (en) * | 2018-12-28 | 2023-02-16 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
WO2020157709A1 (en) | 2019-02-01 | 2020-08-06 | Pfizer Inc. | Combination of a cdk inhibitor and a pim inhibitor |
EP3923949A1 (en) * | 2019-02-15 | 2021-12-22 | Incyte Corporation | Cyclin-dependent kinase 2 biomarkers and uses thereof |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2020186101A1 (en) | 2019-03-12 | 2020-09-17 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
CA3141531A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
US20230053328A9 (en) | 2019-05-24 | 2023-02-16 | Pfizer Inc. | Combination therapies using cdk inhibitors |
CN112010844B (zh) * | 2019-05-31 | 2023-07-25 | 中国药科大学 | N-(嘧啶-2-基)香豆素-7-胺衍生物作为蛋白激酶抑制剂的制法和应用 |
TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
CN112094272A (zh) | 2019-06-18 | 2020-12-18 | 北京睿熙生物科技有限公司 | Cdk激酶抑制剂 |
WO2020253808A1 (zh) * | 2019-06-20 | 2020-12-24 | 江苏恒瑞医药股份有限公司 | 一种药物组合物以及其制备方法 |
CN110143948B (zh) * | 2019-06-21 | 2021-05-14 | 上海博悦生物科技有限公司 | Cdk4/6抑制剂、其药物组合物、制备方法及应用 |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN114502196A (zh) | 2019-08-01 | 2022-05-13 | 因赛特公司 | Ido抑制剂的给药方案 |
JP2023509260A (ja) | 2019-08-14 | 2023-03-08 | インサイト・コーポレイション | Cdk2阻害剤としてのイミダゾリルピリミジニルアミン化合物 |
KR20220099970A (ko) | 2019-10-11 | 2022-07-14 | 인사이트 코포레이션 | Cdk2 억제제로서의 이환식 아민 |
MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN112759589B (zh) * | 2019-11-01 | 2022-04-08 | 暨南大学 | 嘧啶并吡啶酮类化合物及其应用 |
CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
CA3156205A1 (en) | 2019-12-03 | 2021-06-10 | Jennifer O'hara Lauchle | Combination therapies for treatment of breast cancer |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
JP2023507141A (ja) * | 2019-12-16 | 2023-02-21 | ルネラ・バイオテック・インコーポレーテッド | 選択的cdk4/6阻害剤のがん治療薬 |
TW202146017A (zh) | 2020-03-05 | 2021-12-16 | 美商輝瑞股份有限公司 | 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合 |
KR20230017165A (ko) | 2020-03-06 | 2023-02-03 | 인사이트 코포레이션 | Axl/mer 및 pd-1/pd-l1 억제제를 포함하는 병행 요법 |
JP2023517697A (ja) * | 2020-03-13 | 2023-04-26 | プロセネスター エルエルシー | CDK阻害剤としてのピリド[2,3-d]ピリミジン-7(8H)-オン |
JP2021167301A (ja) | 2020-04-08 | 2021-10-21 | ファイザー・インク | Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置 |
CA3179692A1 (en) | 2020-04-16 | 2021-10-21 | Incyte Corporation | Fused tricyclic kras inhibitors |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
CA3173678A1 (en) | 2020-05-19 | 2021-11-25 | Jay Copeland Strum | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
WO2021242770A1 (en) * | 2020-05-28 | 2021-12-02 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of viral rna structures |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
CN113880809B (zh) | 2020-07-03 | 2022-10-18 | 盛世泰科生物医药技术(苏州)有限公司 | 一种嘧啶类衍生物及其制备方法和应用 |
AU2021308406A1 (en) | 2020-07-15 | 2023-02-23 | Ctxt Pty Ltd | KAT6 inhibitor methods and combinations for cancer treatment |
US20230321042A1 (en) | 2020-07-20 | 2023-10-12 | Pfizer Inc. | Combination therapy |
US11999752B2 (en) | 2020-08-28 | 2024-06-04 | Incyte Corporation | Vinyl imidazole compounds as inhibitors of KRAS |
WO2022063119A1 (zh) * | 2020-09-24 | 2022-03-31 | 南京济群医药科技股份有限公司 | 一种羟乙磺酸哌柏西利的组合物及药物 |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
WO2022072783A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Bicyclic dione compounds as inhibitors of kras |
WO2022091001A1 (en) | 2020-10-29 | 2022-05-05 | Pfizer Ireland Pharmaceuticals | Process for preparation of palbociclib |
WO2022123419A1 (en) | 2020-12-08 | 2022-06-16 | Pfizer Inc. | Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib |
CN112569361B (zh) * | 2020-12-30 | 2023-01-10 | 扬子江药业集团上海海尼药业有限公司 | 一种哌柏西利干混悬组合物及其制备方法 |
WO2022155941A1 (en) | 2021-01-25 | 2022-07-28 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors |
WO2022162122A1 (en) | 2021-01-29 | 2022-08-04 | Biotx.Ai Gmbh | Genetically verified netosis inhibitor for use in the treatment of a sars-cov2 infection |
WO2022206888A1 (en) | 2021-03-31 | 2022-10-06 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Fgfr阻害剤及びネクチン-4標的化剤を含む併用療法 |
WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2022261159A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
CR20240059A (es) | 2021-07-07 | 2024-03-21 | Incyte Corp | Compuestos tricíclicos como inhibidores de kras. |
US20230114765A1 (en) | 2021-07-14 | 2023-04-13 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
US20230022525A1 (en) | 2021-07-26 | 2023-01-26 | Celcuity Inc. | Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea |
US20230174555A1 (en) | 2021-08-31 | 2023-06-08 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
CN113683612B (zh) * | 2021-09-07 | 2022-06-17 | 山东铂源药业股份有限公司 | 一种帕布昔利布的制备方法 |
WO2023040914A1 (zh) * | 2021-09-14 | 2023-03-23 | 甘李药业股份有限公司 | 一种cdk4/6抑制剂的医药用途 |
WO2023049697A1 (en) | 2021-09-21 | 2023-03-30 | Incyte Corporation | Hetero-tricyclic compounds as inhibitors of kras |
CA3234375A1 (en) | 2021-10-01 | 2023-04-06 | Incyte Corporation | Pyrazoloquinoline kras inhibitors |
IL312114A (en) | 2021-10-14 | 2024-06-01 | Incyte Corp | Quinoline compounds as Kras inhibitors |
US20230226040A1 (en) | 2021-11-22 | 2023-07-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a kras inhibitor |
WO2023102184A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Bicyclic amine compounds as cdk12 inhibitors |
WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
WO2023107525A1 (en) | 2021-12-10 | 2023-06-15 | Eli Lilly And Company | Cdk4 and 6 inhibitor in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in patients previously treated with a cdk4 and 6 inhibitor |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
WO2023114264A1 (en) | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
US20230192722A1 (en) | 2021-12-22 | 2023-06-22 | Incyte Corporation | Salts and solid forms of an fgfr inhibitor and processes of preparing thereof |
WO2023168686A1 (en) | 2022-03-11 | 2023-09-14 | Qilu Regor Therapeutics Inc. | Substituted cyclopentanes as cdk2 inhibitors |
WO2023116884A1 (en) | 2021-12-24 | 2023-06-29 | Qilu Regor Therapeutics Inc. | Cdk2 inhibitors and use thereof |
CN114456180B (zh) * | 2022-02-18 | 2023-07-25 | 贵州大学 | 用于治疗和/或预防恶性肿瘤的化合物及药物制剂和应用 |
WO2023172921A1 (en) | 2022-03-07 | 2023-09-14 | Incyte Corporation | Solid forms, salts, and processes of preparation of a cdk2 inhibitor |
HUP2200147A1 (hu) * | 2022-05-10 | 2023-11-28 | Egyt Gyogyszervegyeszeti Gyar | Palbociclibet és letrozolt tartalmazó gyógyszerkészítmény |
WO2023250430A1 (en) | 2022-06-22 | 2023-12-28 | Incyte Corporation | Bicyclic amine cdk12 inhibitors |
EP4302755A1 (en) | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing an amino acid |
EP4302832A1 (en) | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing glucono delta lactone |
US20240101557A1 (en) | 2022-07-11 | 2024-03-28 | Incyte Corporation | Fused tricyclic compounds as inhibitors of kras g12v mutants |
CN117430597A (zh) * | 2022-07-14 | 2024-01-23 | 浙江同源康医药股份有限公司 | 用作cdk4激酶抑制剂的化合物及其应用 |
WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
WO2024049926A1 (en) | 2022-08-31 | 2024-03-07 | Arvinas Operations, Inc. | Dosage regimens of estrogen receptor degraders |
WO2024097206A1 (en) | 2022-11-02 | 2024-05-10 | Petra Pharma Corporation | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease |
WO2024100236A1 (en) | 2022-11-11 | 2024-05-16 | Astrazeneca Ab | Combination therapies for the treatment of cancer |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055148A1 (en) * | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
WO2001070741A1 (en) * | 2000-03-06 | 2001-09-27 | Warner-Lambert Company | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
WO2002064594A2 (en) * | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5618982A (en) | 1979-06-14 | 1981-02-23 | Wellcome Found | Pyrimidine derivatives and medicinal drug containing them |
US4959474A (en) | 1979-06-14 | 1990-09-25 | Burroughs Wellcome Co. | Dialkoxy pyridopyrimidine compounds |
AU532842B2 (en) | 1979-06-14 | 1983-10-13 | Wellcome Foundation Limited, The | Alkoxybenzyl pyridopyrimioines |
AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5426110A (en) | 1993-10-06 | 1995-06-20 | Eli Lilly And Company | Pyrimidinyl-glutamic acid derivatives |
GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
US5801183A (en) | 1995-01-27 | 1998-09-01 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
US5620981A (en) * | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
AU2521597A (en) | 1996-04-12 | 1997-11-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyramidine derivatives |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
EP0964864B1 (en) * | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
KR20010082501A (ko) | 1997-10-27 | 2001-08-30 | 개리 이. 프라이드만 | 4-아미노티아졸 유도체, 그 제조방법 및 싸이클린-의존성키나아제의 억제제로서의 이용방법 |
PL344248A1 (en) * | 1998-05-26 | 2001-10-22 | Warner Lambert Co | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
EP1557168B1 (en) | 1999-07-26 | 2011-11-16 | Msd K.K. | Biarylurea Derivatives |
MXPA02001108A (es) | 1999-09-15 | 2002-08-20 | Warner Lambert Co | Pieridinonas como inhibidores de la cinasa. |
MXPA02011263A (es) | 2000-08-04 | 2003-03-10 | Warner Lambert Co | 2-(4-piridil)amino-6-dialcoxifenil- pirido(2,3-d) pirimidin-7-onas. |
JP2004508372A (ja) | 2000-09-01 | 2004-03-18 | グラクソ グループ リミテッド | オキシインドール誘導体 |
GB0101686D0 (en) | 2001-01-23 | 2001-03-07 | Cancer Res Campaign Tech | Cyclin dependent kinase inhibitors |
ES2262899T3 (es) | 2001-12-17 | 2006-12-01 | Smithkline Beecham Corporation | Derivados de pirazolopiridazina. |
DK1470124T3 (da) | 2002-01-22 | 2006-04-18 | Warner Lambert Co | 2-(Pyridin-2-yl amino)-pyrido[2,3]pyrimidin-7-oner |
WO2004032882A2 (en) | 2002-10-10 | 2004-04-22 | Smithkline Beecham Corporation | Chemical compounds |
EP1567112B1 (en) | 2002-11-22 | 2008-10-15 | Smithkline Beecham Corporation | THIAZOLIDIN-4-ONES FOR INHIBITING hYAK3 PROTEINS |
US20050009849A1 (en) * | 2003-01-03 | 2005-01-13 | Veach Darren R. | Pyridopyrimidine kinase inhibitors |
DE602004021558D1 (de) | 2003-01-17 | 2009-07-30 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
ES2312968T3 (es) | 2003-02-27 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos novedosos. |
PL1648889T3 (pl) | 2003-07-11 | 2009-03-31 | Warner Lambert Co | Sól izetionian selektywnego inhibitora CDK4 |
KR20090052385A (ko) | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온의합성 |
-
2003
- 2003-01-10 DK DK03700058T patent/DK1470124T3/da active
- 2003-01-10 AU AU2003237009A patent/AU2003237009B2/en active Active
- 2003-01-10 ES ES03700058T patent/ES2251677T3/es not_active Expired - Lifetime
- 2003-01-10 BR BR122016021801A patent/BR122016021801B8/pt not_active IP Right Cessation
- 2003-01-10 AP APAP/P/2004/003085A patent/AP1767A/en active
- 2003-01-10 BR BRPI0307057A patent/BRPI0307057B8/pt active IP Right Grant
- 2003-01-10 CN CN2011101150746A patent/CN102295643B/zh not_active Expired - Lifetime
- 2003-01-10 KR KR1020067018532A patent/KR20060111716A/ko not_active Application Discontinuation
- 2003-01-10 SI SI200330164T patent/SI1470124T1/sl unknown
- 2003-01-10 KR KR1020047011276A patent/KR100669578B1/ko active IP Right Grant
- 2003-01-10 CN CN2010102557666A patent/CN101906104B/zh not_active Expired - Lifetime
- 2003-01-10 JP JP2003562114A patent/JP4291696B2/ja not_active Expired - Lifetime
- 2003-01-10 ME MEP-2008-461A patent/ME00230B/me unknown
- 2003-01-10 GE GE5674A patent/GEP20063909B/en unknown
- 2003-01-10 IL IL16272103A patent/IL162721A0/xx unknown
- 2003-01-10 CN CN038025566A patent/CN101001857B/zh not_active Expired - Lifetime
- 2003-01-10 EA EA200400860A patent/EA007395B3/ru active Protection Beyond IP Right Term
- 2003-01-10 DE DE60303009T patent/DE60303009T2/de not_active Expired - Lifetime
- 2003-01-10 EP EP03700058A patent/EP1470124B1/en not_active Expired - Lifetime
- 2003-01-10 RS YUP-598/04A patent/RS51044B/sr unknown
- 2003-01-10 CA CA2473026A patent/CA2473026C/en not_active Expired - Lifetime
- 2003-01-10 PL PL372046A patent/PL218692B1/pl unknown
- 2003-01-10 MX MXPA04005939A patent/MXPA04005939A/es active IP Right Grant
- 2003-01-10 WO PCT/IB2003/000059 patent/WO2003062236A1/en active Application Filing
- 2003-01-10 NZ NZ534069A patent/NZ534069A/en not_active IP Right Cessation
- 2003-01-10 PL PL391191A patent/PL220952B1/pl unknown
- 2003-01-10 AT AT03700058T patent/ATE314370T1/de active
- 2003-01-10 OA OA1200400189A patent/OA12755A/en unknown
- 2003-01-14 DO DO2003000561A patent/DOP2003000561A/es unknown
- 2003-01-14 NI NI200300008A patent/NI200300008A/es unknown
- 2003-01-16 US US10/345,778 patent/US6936612B2/en not_active Expired - Lifetime
- 2003-01-16 PE PE2003000050A patent/PE20030975A1/es active IP Right Grant
- 2003-01-17 GT GT200300005A patent/GT200300005A/es unknown
- 2003-01-20 AR ARP030100158A patent/AR038814A1/es active IP Right Grant
- 2003-01-20 MY MYPI20030182A patent/MY134818A/en unknown
- 2003-01-21 SV SV2003001459A patent/SV2004001459A/es not_active Application Discontinuation
- 2003-01-21 HN HN2003000039A patent/HN2003000039A/es unknown
- 2003-01-21 TW TW092101242A patent/TWI343920B/zh active
- 2003-01-21 UY UY27617A patent/UY27617A1/es not_active Application Discontinuation
- 2003-01-22 PA PA20038563701A patent/PA8563701A1/es unknown
- 2003-10-01 UA UA20040706104A patent/UA79444C2/uk unknown
-
2004
- 2004-06-16 IS IS7323A patent/IS2423B/is unknown
- 2004-06-18 ZA ZA2004/04840A patent/ZA200404840B/en unknown
- 2004-06-24 IL IL162721A patent/IL162721A/en active Protection Beyond IP Right Term
- 2004-07-07 TN TNP2004000126A patent/TNSN04126A1/fr unknown
- 2004-07-15 MA MA27785A patent/MA27166A1/fr unknown
- 2004-07-19 HR HRP20040660AA patent/HRP20040660B1/hr not_active IP Right Cessation
- 2004-07-22 CO CO04069500A patent/CO5700765A2/es not_active Application Discontinuation
- 2004-07-22 EC EC2004005201A patent/ECSP045201A/es unknown
- 2004-08-20 NO NO20043484A patent/NO329350B1/no not_active IP Right Cessation
-
2005
- 2005-01-28 US US11/046,126 patent/US7208489B2/en not_active Ceased
-
2006
- 2006-03-08 CY CY20061100324T patent/CY1105686T1/el unknown
-
2007
- 2007-04-11 US US11/734,200 patent/US7456168B2/en not_active Expired - Lifetime
- 2007-09-04 HK HK07109578.4A patent/HK1104296A1/xx not_active IP Right Cessation
-
2009
- 2009-04-20 IL IL198243A patent/IL198243A/en active IP Right Grant
-
2010
- 2010-01-05 EC EC2010005201A patent/ECSP105201A/es unknown
-
2011
- 2011-01-10 HK HK11100169.2A patent/HK1146048A1/xx not_active IP Right Cessation
- 2011-11-02 AR ARP110104062A patent/AR083686A2/es active IP Right Grant
-
2012
- 2012-03-07 HK HK12102320.3A patent/HK1162026A1/xx not_active IP Right Cessation
- 2012-03-19 CR CR20120129A patent/CR20120129A/es unknown
-
2017
- 2017-03-01 HU HUS1700009C patent/HUS1700009I1/hu unknown
- 2017-03-01 NL NL300863C patent/NL300863I2/nl unknown
- 2017-03-15 LU LU00009C patent/LUC00009I2/en unknown
- 2017-03-16 BE BE2017C005C patent/BE2017C005I2/fr unknown
- 2017-03-17 CY CY2017011C patent/CY2017011I1/el unknown
- 2017-04-19 FR FR17C1012C patent/FR17C1012I2/fr active Active
- 2017-04-19 NO NO2017014C patent/NO2017014I2/no unknown
- 2017-04-28 LT LTPA2017013C patent/LTC1470124I2/lt unknown
- 2017-05-04 HU HUS1700019C patent/HUS1700019I1/hu unknown
-
2018
- 2018-07-27 US US16/048,143 patent/USRE47739E1/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001055148A1 (en) * | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
WO2001070741A1 (en) * | 2000-03-06 | 2001-09-27 | Warner-Lambert Company | 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
WO2002064594A2 (en) * | 2001-02-12 | 2002-08-22 | F. Hoffmann-La Roche Ag | 6-substituted pyrido-pyrimidines |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20040660B1 (hr) | 2-(PIRIDIN-2-ILAMINO)-PIRIDO[2,3-d]PIRIMIDIN-7-ONI | |
BRPI0406809A (pt) | Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular | |
WO2007013896A3 (en) | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors | |
UY28970A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
NO20031794D0 (no) | Nye forbindelser | |
DK1343782T3 (da) | Pyrimidinaminer som angiogenesemodulatorer | |
WO2006004636A3 (en) | Fused heterocyclic kinase inhibitors | |
PA8637601A1 (es) | Compuestos moduladores de la actividad de c-kit y usos de los mismos | |
WO2005040169A3 (en) | Fused heterocyclic compounds as serotonin receptor modulators | |
DK1458713T3 (da) | Indolinonderivater anvendelige som proteinkinaseinhibitorer | |
NO20080418L (no) | Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme | |
ATE546452T1 (de) | Pyrazolopyrrolderivate als proteinkinaseinhibitoren | |
NO20045025L (no) | Nye forbindelser | |
WO2002083622A3 (en) | Novel aminophenyl ketone derivatives | |
MA53485A (fr) | Procédés de préparation de 4-(8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl] imidazo[1,5-a]-pyrazin-1-yl)n-(pyridin-2-yl)-benzamide | |
MXPA03011167A (es) | Derivados de carbolina utiles como ihibidores de pdev. | |
EP3997088A4 (en) | DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS | |
CR7392A (es) | 2- (piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas | |
DK1490363T3 (da) | Fremgangsmåder til fremstilling af 2-7-chlor-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)1-isoindolinon | |
CU23294A3 (es) | 2(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
B1PR | Patent granted | ||
PNAN | Change of the applicant name, address/residence |
Owner name: WARNER-LAMBERT COMPANY LLC, US |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20181224 Year of fee payment: 17 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200108 Year of fee payment: 18 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20210107 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20211228 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20230110 |